Selvita is moving towards a new phase of development. Company and management changes, as well as the purchase of land to pursue organic growth, as a starting point for a new development strategy



Krakow, POLAND, February 1, 2022 /PRNewswire/ — Selvita (WSE: SLV) – one of the largest preclinical contract research organizations Europe, today announced changes to its leadership and organizational structure, aimed at supporting the Company’s continued growth and strengthening its position in the global marketplace. At the same time, Selvita informs about the signing of a preliminary contract for the purchase of another piece of land in order to expand its own laboratory space and ensure additional organic growth in Krakow, Poland.

Selvita lays the foundations for the future development of the Group through the integration of services in the field of drug discovery, the integration of business development activities and the creation of a department supporting the management of operations and investments.

Integration of the field of drug discovery as a starting point for a new development strategy

Integrated departments providing drug discovery services, operating in KrakowPoznan and Zagrebwill be led by Dr. Adriana Vinter, who assumes the role of Global Head of Drug Discovery and joins Selvita’s Board of Directors. Previously, for the past four years, Dr. Vinter held the position of Managing Director at Fidelta. Following this integration, leveraging Fidelta’s experience and skills in creating value in areas such as inflammation, fibrosis and anti-infectives, Selvita Group intends to develop capabilities in subsequent therapeutic areas, to increase revenues through the expansion of the scale of operations and to provide customers with an increasingly comprehensive service offering.

“I am delighted to welcome Dr. Adriana Vinter to Selvita’s Board of Directors. Dr. Vinter brings valuable experience in creating value for customers gained while running Fidelta. These skills will help us further develop Selvita’s offering and fully explore the Group’s potential in drug discovery,”- comments Boguslaw SieczkowskiSelvita CEO.

Business development and sales integration is the key to strengthening market position

The Company also intends to integrate its business development and sales activities. dr. Milosz Gruca, who will assume the functions of Chief Commercial Officer, Executive Vice President, will lead the teams in charge of the development and commercialization of Selvita and Fidelta’s integrated service offer in the field of drug discovery and development. This integration and the reinforcement of the business development team over the last year will help Selvita to establish a solid position among global CRO companies, in particular in the North American and British markets, the most important for the outsourcing of the research.

“For several years now, Dr. Milosz Gruca successfully managed the business development and sales of Selvita’s services, for example in the United States and the United Kingdom. I’m sure Dr. Gruca will also be successful in growing our integrated service offering and managing global business development efforts. I firmly believe that through these changes, we will become a strategic partner of choice for pharmaceutical and biotechnology companies,” adds Sieczkowski.

Continued organic growth

Additionally, Selvita plans to continue its dynamic organic growth, and access to additional research space will be a crucial factor in this. The Company has already taken the first step in this direction by signing a preliminary contract for the purchase of another piece of land near the new Selvita research center currently under construction. Ultimately, the Company will create new workstations for approximately 1,000 scientists and specialists in its new research center in Krakow, Poland.

The scale of the group’s growing operations and its subsequent development plans led to the creation of the position of chief operating officer, assumed by Dr. Miroslawa Zydron, the current head of the chemistry department. Dr. Zydron will be responsible for the Group’s operational activities, investments and infrastructure management.

“To become an industry leader, we must not only continually expand our service portfolio, but also gradually expand our existing operations. To this end, we have created a unit responsible for operational activities. I am very happy that Dr. Miroslawa Zydron, who built Selvita’s largest department, will lead this new division. His solid management experience will help us maintain the growth momentum and effectively manage the growing scale of the Group’s activities.

We have no intention of slowing down and we want to continue intensive development in the years to come. Many new challenges await us, however, I am sure that together we can achieve the ambitious goals we have set ourselves, create the best quality services for our customers, build the company’s market value for our shareholders, and at the same time become a better employer for our scientists and specialists”, sums up Boguslaw Sieczkowski.

The organizational and management changes mark the beginning of the construction of a new development strategy for the Selvita Group, which the reinforced management team will work on in the first quarter of this year.

About Selvita [SLV]

Selvita is a preclinical contract research organization that provides multidisciplinary support to solve unique research challenges in drug discovery, regulatory studies, and research and development. Selvita Group includes Fidelta, a drug discovery services company specializing in infectious diseases, inflammation and fibrosis, and Ardigen, a bioinformatics company leveraging advanced artificial intelligence methods for new precision medicine, and Selvita Group, established in 2007, operates globally with nearly 900 qualified employees, more than 40% of whom hold PhDs. The Company’s research sites are located at Krakow (HQ) and Poznan, Polandas good as Zagreb, Croatia (Fidelta). All Group companies offer highly synergistic technologies and services. International offices are located at Cambridge, MAand San Francisco Bay Areain the United States, as well as in Cambridge, United Kingdom.

Selvita is listed on the Warsaw Stock Exchange (WSE: SLV). For more information, please visit

View original content: – plot-of-land-for-organic-growth-as-a-starting-point-for-a-new-development-strategy-301472465.html


Source link


About Author

Comments are closed.